155 related articles for article (PubMed ID: 38454604)
1. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia.
Alayoubi AM; Khawaji ZY; Mohammed MA; Mercier FE
Ann Hematol; 2024 Jun; 103(6):1805-1817. PubMed ID: 37736806
[TBL] [Abstract][Full Text] [Related]
2. Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.
Moiani A; Letort G; Lizot S; Chalumeau A; Foray C; Felix T; Le Clerre D; Temburni-Blake S; Hong P; Leduc S; Pinard N; Marechal A; Seclen E; Boyne A; Mayer L; Hong R; Pulicani S; Galetto R; Gouble A; Cavazzana M; Juillerat A; Miccio A; Duclert A; Duchateau P; Valton J
Nat Commun; 2024 Jun; 15(1):4965. PubMed ID: 38862518
[TBL] [Abstract][Full Text] [Related]
3. Role of gene therapy in sickle cell disease.
Raghuraman A; Lawrence R; Shetty R; Avanthika C; Jhaveri S; Pichardo BV; Mujakari A
Dis Mon; 2024 Jul; 70(7):101689. PubMed ID: 38326171
[TBL] [Abstract][Full Text] [Related]
4. Warrior Spirit: An Interview with Victoria Gray, Sickle Cell Pioneer.
Gray V; Thomas U; Davies K
CRISPR J; 2024 Feb; 7(1):5-11. PubMed ID: 38353619
[No Abstract] [Full Text] [Related]
5. Verve Pauses Enrollment in Base Editing Trial after Adverse Events.
Philippidis A
Hum Gene Ther; 2024 May; 35(9-10):313-316. PubMed ID: 38781422
[No Abstract] [Full Text] [Related]
6. Autologous gene therapy for hemoglobinopathies: From bench to patient's bedside.
Locatelli F; Cavazzana M; Frangoul H; Fuente J; Algeri M; Meisel R
Mol Ther; 2024 May; 32(5):1202-1218. PubMed ID: 38454604
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
8. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
9. The Cas9 Hammer-and Sickle: A Challenge for Genome Editors.
Urnov FD
CRISPR J; 2021 Feb; 4(1):6-13. PubMed ID: 33616446
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
11. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
12. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021.
GBD 2021 Sickle Cell Disease Collaborators
Lancet Haematol; 2023 Aug; 10(8):e585-e599. PubMed ID: 37331373
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice.
Everette KA; Newby GA; Levine RM; Mayberry K; Jang Y; Mayuranathan T; Nimmagadda N; Dempsey E; Li Y; Bhoopalan SV; Liu X; Davis JR; Nelson AT; Chen PJ; Sousa AA; Cheng Y; Tisdale JF; Weiss MJ; Yen JS; Liu DR
Nat Biomed Eng; 2023 May; 7(5):616-628. PubMed ID: 37069266
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
